Related references
Note: Only part of the references are listed.Regulation of neutrophil function by selective targeting of glycan epitopes expressed on the integrin CD11b/CD18
Matthias Kelm et al.
FASEB JOURNAL (2020)
How do chemokines navigate neutrophils to the target site: Dissecting the structural mechanisms and signaling pathways
Krishna Rajarathnam et al.
CELLULAR SIGNALLING (2019)
IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease
Lyssia Belarif et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases
Samuel J. S. Rubin et al.
NATURE COMMUNICATIONS (2019)
Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study
Lauren E. Mokry et al.
SCIENTIFIC REPORTS (2019)
The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases
Eva M. Garcia-Cuesta et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Targeting Cancer Stemness in the Clinic: From Hype to Hope
Caner Saygin et al.
CELL STEM CELL (2019)
Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases
Susanna Nikolaus et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2018)
C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions
Vishnu Mohanan et al.
SCIENCE (2018)
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease
Katrina M. de lange et al.
NATURE GENETICS (2017)
Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles
Erik Andersson et al.
PLOS ONE (2017)
Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor Antagonists
Nicholas Kindon et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Mend Your Fences The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease
Eva Martini et al.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2017)
Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience
T. Billiet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
Isabelle Cleynen et al.
LANCET (2016)
A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus
Elizabeth A. McKie et al.
PLOS ONE (2016)
Targeting chemokine receptors in disease - a case study of CCR4
Roberto Solari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) - a selective CXCR2 antagonist - in healthy adult subjects
Bruce E. Miller et al.
BMC PHARMACOLOGY & TOXICOLOGY (2015)
The innate immune system and inflammatory bowel disease
Julie M. Davies et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Cytokines in inflammatory bowel disease
Markus F. Neurath
NATURE REVIEWS IMMUNOLOGY (2014)
Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation
Katia De Filippo et al.
BLOOD (2013)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins et al.
NATURE (2012)
Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice
Shane E. Russell et al.
PLOS ONE (2012)
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans
Aili L. Lazaar et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Reciprocal regulation of CXCR4 and CXCR7 in intestinal mucosal homeostasis and inflammatory bowel disease
Lael Werner et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Genetics and pathogenesis of inflammatory bowel disease
Bernard Khor et al.
NATURE (2011)
Neutrophil chemokines GCP-2 and GRO-α in patients with inflammatory bowel disease
Mohammed A. Alzoghaibi et al.
JOURNAL OF DIGESTIVE DISEASES (2008)
Assessment of reliability and validity of IBD phenotyping within the national institutes of diabetes and digestive and kidney diseases (NIDDK) IBD genetics consortium (IBDGC)
Themistocles Dassopoulos et al.
INFLAMMATORY BOWEL DISEASES (2007)
Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis
John D. Rioux et al.
NATURE GENETICS (2007)
Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123):: A potent, orally bioavailable CXCR2/CXCR1 receptor antagonist
Michael P. Dwyer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Chemokine production by buccal epithelium as a distinctive feature of pediatric Crohn disease
GM Damen et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2006)
Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease
K Mitsuyama et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Share Paper
